Prasugrel inhibits platelet-enhanced pro-inflammatory CD4+ T cell responses in humans

Atherosclerosis

Volumn 239, Issue 1, 2015, Pages 283-286

  Johnston, L R ^a,b   La Flamme, A C ^a,b,c   Larsen, P D ^a,b,d   Harding, S A ^a,b,e  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b Wellington Cardiovascular Research Group   (New Zealand)

^c MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e WELLINGTON HOSPITAL   (New Zealand)

Author keywords

Antiplatelet therapy; Atherosclerosis; Inflammation; Platelets

Indexed keywords

GAMMA INTERFERON; PRASUGREL; CYTOKINE; FIBRINOLYTIC AGENT;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LOADING DRUG DOSE; NORMAL HUMAN; PHENOTYPE; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE FUNCTION; CYTOLOGY; DRUG EFFECTS; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TH1 CELL; TH17 CELL; THROMBOCYTE ACTIVATION; YOUNG ADULT;

ADULT; BLOOD PLATELETS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CROSS-OVER STUDIES; CYTOKINES; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HUMANS; INFLAMMATION; MIDDLE AGED; PLATELET ACTIVATION; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; TH1 CELLS; TH17 CELLS; YOUNG ADULT;

EID: 84921737370     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.01.006     Document Type: Article

References (18)

1. George J.N. Platelets. Lancet 2000, 355:1531-1539.
2. Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science 2010, 328:562-564.
3. von Hundelshausen P., Weber C. Platelets as immune cells - Bridging inflammation and cardiovascular disease. Circ. Res. 2007, 100:27-40.
4. Ware J., Corken A., Khetpal R. Platelet function beyond hemostasis and thrombosis. Curr. Opin. Hematol. 2013, 20:451-456.
5. Totani L., Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2357-2361.
6. Huo Y.Q., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S., Littman D.R., Weber C., Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. 2003, 9:61-67.
7. Li N. CD4+ T cells in atherosclerosis: regulation by platelets. Thromb. Haemostasis 2013, 109:980-990.
8. Gerdes N., Zhu L., Ersoy M., Hermansson A., Hjemdahl P., Hu H., Hansson G.K., Li N. Platelets regulate CD4 T-cell differentiation via multiple chemokines in humans. Thromb. Haemostasis 2011, 106:353-362.
9. Steinhubl S.R., Badimon J.J., Bhatt D.L., Herbert J.M., Luscher T.F. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc. Med. 2007, 12:113-122.
10. Harding S.A., Sarma J., Din J.N., Maciocia P.M., Newby D.E., Fox K.A. Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus. Heart 2006, 92:1335-1337.
11. Johnston L.R., Larsen P.D., La Flamme A.C., Harding S.A. Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate(R) analyser. Platelets 2013, 24(4):303-307.
12. Tellides G., Tereb D.A., Kirkiles-Smith N.C., Kim R.W., Wilson J.H., Schechner J.S., Lorber M.I., Pober J.S. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000, 403:207-211.
13. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 2008, 453:1051-1057.
14. Taub D.D., Turcovski-Corrales S.M., Key M.L., Longo D.L., Murphy W.J. Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation invitro. J.Immunol. 1996, 156:2095-2103.
15. Fleischer J., Grage-Griebenow E., Kasper B., Heine H., Ernst M., Brandt E., Flad H.D., Petersen F. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J.Immunol. 2002, 169:770-777.
16. Lindemann S., Tolley N.D., Dixon D.A., McIntyre T.M., Prescott S.M., Zimmerman G.A., Weyrich A.S. Activated platelets mediate inflammatory signaling by regulated interleukin 1 beta synthesis. J.Cell Biol. 2001, 154:485-490.
17. Laurat E., Poirier B., Tupin E., Caligiuri G., Hansson G.K., Bariety J., Nicoletti A. Invivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001, 104:197-202.
18. Buono C., Binder C.J., Stavrakis G., Witztum J.L., Glimcher L.H., Lichtman A.H. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1596-1601.